These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37299478)

  • 1. Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications.
    Cai L
    Nutrients; 2023 May; 15(11):. PubMed ID: 37299478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of the diabetic heart.
    Tziakas DN; Chalikias GK; Kaski JC
    Coron Artery Dis; 2005 Nov; 16 Suppl 1():S3-S10. PubMed ID: 16340402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy of pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome.
    Kato T; Inagaki K; Sawai Y; Kanayama H; Katada N; Itoh M
    Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):554-8. PubMed ID: 21472664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
    Bronander KA; Bloch MJ
    Vasc Health Risk Manag; 2007; 3(2):181-90. PubMed ID: 17580728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin tags: a useful clinical sign for insulin resistance?
    Crook M
    Eur J Dermatol; 2012; 22(1):5-6. PubMed ID: 22237167
    [No Abstract]   [Full Text] [Related]  

  • 6. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer.
    Gallagher EJ; LeRoith D
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S233-9. PubMed ID: 23882051
    [No Abstract]   [Full Text] [Related]  

  • 7. [Relation between sexual dysfunction and metabolic syndrome].
    Zsoldos M; Pajor A; Pusztafalvi H
    Orv Hetil; 2019 Jan; 160(3):98-103. PubMed ID: 30640528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the metabolic syndrome a real clinical entity and should it receive drug treatment?
    Darsow T; Kendall D; Maggs D
    Curr Diab Rep; 2006 Nov; 6(5):357-64. PubMed ID: 17076996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interrupting the natural history of diabetes mellitus: lifestyle, pharmacological and surgical strategies targeting disease progression.
    Khavandi K; Brownrigg J; Hankir M; Sood H; Younis N; Worth J; Greenstein A; Soran H; Wierzbicki A; Goldsmith DJ
    Curr Vasc Pharmacol; 2014 Jan; 12(1):155-67. PubMed ID: 22272898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
    Després JP
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of dislipemia in patients with metabolic syndrome or diabetes mellitus].
    Millán J;
    Med Clin (Barc); 2007 May; 128(20):786-94. PubMed ID: 17568508
    [No Abstract]   [Full Text] [Related]  

  • 12. Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension.
    Cerezo C; Segura J; Praga M; Ruilope LM
    Curr Hypertens Rep; 2013 Jun; 15(3):196-203. PubMed ID: 23519746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orlistat: a review of its use in the management of patients with obesity.
    Curran MP; Scott LJ
    Drugs; 2004; 64(24):2845-64. PubMed ID: 15563254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options.
    Potenza MA; Nacci C; De Salvia MA; Sgarra L; Collino M; Montagnani M
    Pharmacol Res; 2017 Jun; 120():226-241. PubMed ID: 28408314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus.
    Katsiki N; Anagnostis P; Kotsa K; Goulis DG; Mikhailidis DP
    Curr Pharm Des; 2019; 25(18):2051-2059. PubMed ID: 31298151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
    Basile J; Houston M; Ferrario CM
    J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
    [No Abstract]   [Full Text] [Related]  

  • 17. Age- and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the SardiNIA Study.
    Scuteri A; Najjar SS; Orru' M; Albai G; Strait J; Tarasov KV; Piras MG; Cao A; Schlessinger D; Uda M; Lakatta EG
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):532-41. PubMed ID: 19321325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing cardiovascular disease and diabetes: a call to action from the ADA and AHA.
    Wyne KL
    J Cardiometab Syndr; 2006; 1(3):220-1. PubMed ID: 17679801
    [No Abstract]   [Full Text] [Related]  

  • 19. Turning attention to the young.
    Weber MA
    J Clin Hypertens (Greenwich); 2011 May; 13(5):321-2. PubMed ID: 21545392
    [No Abstract]   [Full Text] [Related]  

  • 20. MANAGEMENT OF ENDOCRINE DISEASE: Rationale and current evidence for testosterone therapy in the management of obesity and its complications.
    Lapauw B; Kaufman JM
    Eur J Endocrinol; 2020 Dec; 183(6):R167-R183. PubMed ID: 33105105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.